Ani Pharmaceuticals (ANIP) Asset Writedowns and Impairment (2010 - 2024)

Ani Pharmaceuticals (ANIP) has 6 years of Asset Writedowns and Impairment data on file, last reported at $7.6 million in Q4 2024.

• For the quarter ending Q4 2024, Asset Writedowns and Impairment changed N/A year-over-year to $7.6 million; the trailing twelve-month figure through Dec 2025 stood at $7.6 million (changed 0.0% YoY), and the FY2025 full-year result was $767000.0, down 89.91% from the prior year.
• Asset Writedowns and Impairment improved to $7.6 million in Q4 2024, from -$1000.0 in the prior quarter.
• In the past five years, Asset Writedowns and Impairment ranged from a high of $7.6 million in Q4 2024 to a low of -$1000.0 in Q3 2022.
• A 4-year average of $2.1 million and a median of $341000.0 in 2020 frame the typical range for Asset Writedowns and Impairment.
• Across the five-year window, Asset Writedowns and Impairment soared 354.67% in 2020 and soared 596.19% in 2021, its largest moves.
• Tracing ANIP's Asset Writedowns and Impairment over 4 years: stood at $341000.0 in 2020, then soared by 596.19% to $2.4 million in 2021, then plunged by 100.04% to -$1000.0 in 2022, then soared by 760100.0% to $7.6 million in 2024.
• Business Quant data shows ANIP's Asset Writedowns and Impairment at $7.6 million in Q4 2024, -$1000.0 in Q3 2022, and $2.4 million in Q4 2021.